compound 2a

Compound 2a is a non-specific research identifier referring to at least two distinct experimental small molecules identified in pharmacological literature. One version of compound 2a is an isoindoline-1,3-dione derivative being investigated as a potential anticonvulsant for the treatment of epilepsy. In preclinical animal models, this compound has demonstrated the ability to increase seizure latency, reduce seizure duration, and lower mortality rates, although its specific molecular target remains unidentified. Another compound 2a is a novel small molecule inhibitor of the mammalian target of rapamycin (mTOR), identified through virtual screening and optimization for the radiosensitization of hepatocellular carcinoma (HCC). By inhibiting the overactivated mTOR pathway, this compound aims to enhance the efficacy of radiotherapy in HCC patients. Both entities are currently in the early research or preclinical stages of development.